This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UBX UNITY Biotechnology (UBX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About UNITY Biotechnology Stock (NASDAQ:UBX) Get UNITY Biotechnology alerts:Sign Up Key Stats Today's Range$0.20▼$0.2050-Day Range$0.18▼$0.8852-Week Range$0.20▼$1.23VolumeN/AAverage Volume808,608 shsMarket Capitalization$3.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Read More Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UNITY Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UBX Stock News HeadlinesUnity Stock Crashes Nearly 50% After Nasdaq Delisting NoticeJune 30, 2025 | finance.yahoo.comUnity Biotechnology stock plunges after Nasdaq delisting noticeJune 30, 2025 | za.investing.comPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, SpaceX, BlackRock, Goldman Sachs, Visa, Boeing, and more boarded Air Force One with President Trump to visit China. A U.S.-China trade deal would ignite a Melt Up in U.S. stocks, sending the market into a frenzy.May 30 at 1:00 AM | Stansberry Research (Ad)Unity Biotechnology Inc News (UBX) - Investing.comJune 26, 2025 | investing.comUBX Unity Biotechnology, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comHC Wainwright & Co. Downgrades Unity Biotechnology (UBX)May 28, 2025 | msn.comUnity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho SecuritiesMay 18, 2025 | theglobeandmail.comBay Area biotech company Unity lays off every single worker, including CEOMay 6, 2025 | msn.comSee More Headlines UBX Stock Analysis - Frequently Asked Questions How were UNITY Biotechnology's earnings last quarter? UNITY Biotechnology, Inc. (NASDAQ:UBX) issued its earnings results on Tuesday, April, 22nd. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.43). When did UNITY Biotechnology's stock split? UNITY Biotechnology's stock reverse split before market open on Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did UNITY Biotechnology IPO? UNITY Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager. What other stocks do shareholders of UNITY Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK). Company Calendar Last Earnings4/22/2025Today5/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UBX CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees60Year Founded2009Profitability EPS (Trailing Twelve Months)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.99 million Net MarginsN/A Pretax MarginN/A Return on Equity-246.82% Return on Assets-58.81% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book0.51Miscellaneous Outstanding Shares17,212,000Free Float16,214,000Market Cap$3.44 million OptionableOptionable Beta0.92 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:UBX) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UNITY Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share UNITY Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
